ASH 2022 | The impact of age and comorbidities on the outcomes of patients with CLL treated with BTK inhibitors
In this video, Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, briefly discusses the impact of age and comorbidities on the outcomes of patients with chronic lymphocytic leukemia (CLL) treated with various Bruton’s tyrosine kinase (BTK) inhibitors. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen, Roche, AbbVie, BeiGene, AstraZeneca: Research Funding; Janssen, Roche, AbbVie, BeiGene, AstraZeneca, MSD: Speakers Bureau; Beigene: Other: Travel Support; Janssen, AbbVie, Lilly, AstraZeneca, BeiGene, MSD: Consultancy.
